Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 15/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.63 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6209805 | 0.98 | SLC6A3 (0.67) | DPP4SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL24510661 | 0.98 | SLC6A3 (0.67) | DPP4SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL24509676 | 0.96 | DPP4 (0.59) | DPP4SLC6A3SLC6A4SLC6A2MAOA | |
| SCHEMBL987779 | 0.91 | MAOA (0.61) | DPP4SLC6A3SLC6A4SLC6A2MAOA | |
| SCHEMBL10577936 | 0.81 | DPP4 (0.67) | DPP4SLC6A3SLC6A4SLC6A2MAOA | |
| SCHEMBL7888175 | 0.79 | SLC6A3 (0.96) | DPP4SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL8350789 | 0.79 | DPP4 (0.64) | DPP4SLC6A3SLC6A4SLC6A2MAOA | |
| SCHEMBL2636952 | 0.79 | ALDH1A1 (0.46) | DPP4SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5495766 | 0.79 | SLC6A3 (0.96) | DPP4SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL294582 | 0.78 | DPP4 (1.00) | DPP4SLC6A3SLC6A4SLC6A2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4261211-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | Etern Biopharma (Shanghai) Co., Ltd. (CN) | 2023-10-18 | — | — | EP | disclosed |
| WO-2022122037-A1 | DIHYDROISOQUINOLINONE DERIVATIVE AND APPLICATION THEREOF | 上海奕拓医药科技有限责任公司 | 2022-06-16 | — | — | WO | disclosed |
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | BAYER HEALTHCARE AG (DE) | 2005-10-20 | — | — | US | disclosed |
| EP-1507763-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-23 | — | — | EP | disclosed |
| WO-2003097607-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234096-A1 | Tetrahydroisoquinoline derivatives | PPARD, PPARG, PPARA | DPP4 267/4885SLC6A3 3645/4885SLC6A4 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.